Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vi Polysaccharide-Specific Immune Response via CRM197-Conjugation (Vi-CRM197)
- Target
- Vi-CRM197
- Molecular classification
- Polysaccharide-protein conjugate, Vaccine
01
Overview
The Vi Polysaccharide-Specific Immune Response via CRM197-Conjugation refers to the adaptive immune response elicited against the Vi capsular polysaccharide of *Salmonella enterica* serovar Typhi when presented as a conjugate vaccine with the carrier protein CRM197. This strategy enhances immunogenicity, particularly in infants and young children, by converting the immune response from T cell-independent to T cell-dependent, resulting in improved long-term protection against typhoid fever.
- Other names
- Vi-CRM197 conjugate vaccineTyphoid conjugate vaccineTCVVi capsular polysaccharide-CRM197 conjugate
02
Mechanism of action
Induction of a T-cell dependent immune response to the Vi capsular polysaccharide of *Salmonella enterica* serovar Typhi via presentation on CRM197, leading to long-lasting IgG antibody production and immunological memory.
03
Biological functions
Induction of humoral immunityB cell activationT cell activation (via conjugate)Antibody productionImmunological memory formationOpsonizationComplement activation
04
Disease associations
Prevention of typhoid feverInfection
05
Safety considerations
Injection site reactions (pain, redness, swelling)FeverIrritabilityAllergic reactions (rare)
06
Interacting drugs
Vi-CRM197 conjugate vaccine (e.g., Typbar-TCV, PedaTyph)
07
Biomarkers
Anti-Vi IgG antibody titerAnti-Vi IgM antibody titerMemory B cell count
Beyond the preview
Go deeper on Vi Polysaccharide-Specific Immune Response via CRM197-Conjugation (Vi-CRM197).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vi Polysaccharide-Specific Immune Response via CRM197-Conjugation (Vi-CRM197).